417 related articles for article (PubMed ID: 35860285)
1. The Flare of Rheumatic Disease After SARS-CoV-2 Vaccination: A Review.
Xie Y; Liu Y; Liu Y
Front Immunol; 2022; 13():919979. PubMed ID: 35860285
[TBL] [Abstract][Full Text] [Related]
2. Systemic rheumatic disease flares after SARS-CoV-2 vaccination among rheumatology outpatients in New York City.
Barbhaiya M; Levine JM; Bykerk VP; Jannat-Khah D; Mandl LA
Ann Rheum Dis; 2021 Oct; 80(10):1352-1354. PubMed ID: 34158370
[No Abstract] [Full Text] [Related]
3. COVID-19 vaccination and infection status: a cross-sectional survey of patients with rheumatic diseases in China.
Chen C; Huang S; Geng L; Lai P; Dou H; Zhang H; Chen H; Liang J; Sun L
Rheumatol Int; 2024 Apr; 44(4):703-713. PubMed ID: 37897662
[TBL] [Abstract][Full Text] [Related]
4. Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey.
Rider LG; Parks CG; Wilkerson J; Schiffenbauer AI; Kwok RK; Noroozi Farhadi P; Nazir S; Ritter R; Sirotich E; Kennedy K; Larche MJ; Levine M; Sattui SE; Liew JW; Harrison CO; Moni TT; Miller AK; Putman M; Hausmann J; Simard JF; Sparks JA; Miller FW;
Rheumatology (Oxford); 2022 Jun; 61(SI2):SI143-SI150. PubMed ID: 35460240
[TBL] [Abstract][Full Text] [Related]
5. Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine.
Ozdede A; Guner S; Ozcifci G; Yurttas B; Toker Dincer Z; Atli Z; Uygunoğlu U; Durmaz E; Uçar D; Uğurlu S; Saip S; Tabak F; Hamuryudan V; Seyahi E
Rheumatol Int; 2022 Jun; 42(6):973-987. PubMed ID: 35376962
[TBL] [Abstract][Full Text] [Related]
6. Safety of COVID-19 vaccines and disease flares after vaccines in children with rheumatic disease.
Arslanoglu Aydin E; Baglan E; Bagrul I; Tuncez S; Ozdel S; Bulbul M
Postgrad Med; 2022 Aug; 134(6):616-621. PubMed ID: 35535525
[TBL] [Abstract][Full Text] [Related]
7. Anti-SARS-CoV-2 vaccination in adolescent and adult patients with juvenile-onset systemic lupus erythematosus: tolerability and impact on disease activity.
Chighizola CB; Suardi I; Carrea G; Argolini L; Gattinara M; Marino A; Pontikaki I; Caporali R; Gerosa M
Rheumatology (Oxford); 2023 Sep; 62(9):3146-3150. PubMed ID: 36702464
[TBL] [Abstract][Full Text] [Related]
8. Safety and disease flare of autoimmune inflammatory rheumatic diseases: a large real-world survey on inactivated COVID-19 vaccines.
Fan Y; Geng Y; Wang Y; Deng X; Li G; Zhao J; Ji L; Zhang X; Song Z; Zhang H; Sun X; Gao D; Xie W; Huang H; Hao Y; Zhang Z
Ann Rheum Dis; 2022 Mar; 81(3):443-445. PubMed ID: 34824048
[No Abstract] [Full Text] [Related]
9. Safety and immunogenicity of inactivated COVID-19 vaccination in adult rheumatic patients in South China: a prospective study.
Zeng H; Liu H; Liu Z; Zhou X; Lu X; Yan Z; Zhou Y; Dai L; Chen Y; Yang T; Yin Z; Ye Z
Hum Vaccin Immunother; 2022 Nov; 18(5):2090176. PubMed ID: 35878733
[TBL] [Abstract][Full Text] [Related]
10. Coronavirus disease 2019 vaccination uptake and hesitancy among Polish patients with inborn errors of immunity, autoinflammatory syndromes, and rheumatic diseases: A multicenter survey.
Więsik-Szewczyk E; Ziętkiewicz M; Będzichowska A; Napiórkowska-Baran K; Matyja-Bednarczyk A; Felis-Giemza A; Jahnz-Różyk K
Front Immunol; 2022; 13():1010899. PubMed ID: 36275663
[TBL] [Abstract][Full Text] [Related]
11. Adverse events and disease flares after SARS-CoV-2 vaccination in patients with systemic lupus erythematosus.
Barbhaiya M; Levine JM; Siegel CH; Bykerk VP; Jannat-Khah D; Mandl LA
Clin Rheumatol; 2022 May; 41(5):1619-1622. PubMed ID: 34716843
[No Abstract] [Full Text] [Related]
12. Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry.
Machado PM; Lawson-Tovey S; Strangfeld A; Mateus EF; Hyrich KL; Gossec L; Carmona L; Rodrigues A; Raffeiner B; Duarte C; Hachulla E; Veillard E; Strakova E; Burmester GR; Yardımcı GK; Gomez-Puerta JA; Zepa J; Kearsley-Fleet L; Trefond L; Cunha M; Mosca M; Cornalba M; Soubrier M; Roux N; Brocq O; Durez P; Conway R; Goulenok T; Bijlsma JW; McInnes IB; Mariette X
Ann Rheum Dis; 2022 May; 81(5):695-709. PubMed ID: 34972811
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity, breakthrough infection, and underlying disease flare after SARS-CoV-2 vaccination among individuals with systemic autoimmune rheumatic diseases.
Paik JJ; Sparks JA; Kim AHJ
Curr Opin Pharmacol; 2022 Aug; 65():102243. PubMed ID: 35636384
[TBL] [Abstract][Full Text] [Related]
14. Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong.
Li X; Tong X; Yeung WWY; Kuan P; Yum SHH; Chui CSL; Lai FTT; Wan EYF; Wong CKH; Chan EWY; Lau CS; Wong ICK
Ann Rheum Dis; 2022 Apr; 81(4):564-568. PubMed ID: 34686479
[TBL] [Abstract][Full Text] [Related]
15. Is vaccination against COVID-19 associated with autoimmune rheumatic disease flare? A self-controlled case series analysis.
Nakafero G; Grainge MJ; Card T; Mallen CD; Nguyen Van-Tam JS; Williams HC; Abhishek A
Rheumatology (Oxford); 2023 Apr; 62(4):1445-1450. PubMed ID: 36048896
[TBL] [Abstract][Full Text] [Related]
16. Perceived Risk of SARS-CoV-2 at the Start of the COVID-19 Pandemic and Subsequent Vaccination Attitudes in Patients With Rheumatic Diseases: A Longitudinal Analysis.
Duculan R; Mancuso CA
J Clin Rheumatol; 2022 Jun; 28(4):190-195. PubMed ID: 35067512
[TBL] [Abstract][Full Text] [Related]
17. Disease Flare and Reactogenicity in Patients With Rheumatic and Musculoskeletal Diseases Following Two-Dose SARS-CoV-2 Messenger RNA Vaccination.
Connolly CM; Ruddy JA; Boyarsky BJ; Barbur I; Werbel WA; Geetha D; Garonzik-Wang JM; Segev DL; Christopher-Stine L; Paik JJ
Arthritis Rheumatol; 2022 Jan; 74(1):28-32. PubMed ID: 34346185
[TBL] [Abstract][Full Text] [Related]
18. Vaccination of patients with inflammatory rheumatic diseases against SARS-CoV-2: considerations before widespread availability of the vaccines.
Schulze-Koops H; Specker C; Skapenko A
RMD Open; 2021 Feb; 7(1):. PubMed ID: 33627439
[TBL] [Abstract][Full Text] [Related]
19. Side effects and flares risk after SARS-CoV-2 vaccination in patients with systemic lupus erythematosus.
Zavala-Flores E; Salcedo-Matienzo J; Quiroz-Alva A; Berrocal-Kasay A
Clin Rheumatol; 2022 May; 41(5):1349-1357. PubMed ID: 34782941
[TBL] [Abstract][Full Text] [Related]
20. COVID-19 vaccine hesitancy in patients with systemic autoimmune rheumatic disease: an interview-based survey.
Gaur P; Agrawat H; Shukla A
Rheumatol Int; 2021 Sep; 41(9):1601-1605. PubMed ID: 34213580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
